Sanglifehrin derivatives and methods for their production
There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.
1. A compound selected from:
which can also be represented as
which can also be represented as:
including any tautomer thereof; or an isomer thereof in which the C26, 27 C═C bond shown as trans is cis; and including a methanol adduct thereof in which a ketal is formed by the combination of the C-53 keto and the C-15 hydroxyl group and methanol;
or a pharmaceutically acceptable salt thereof.
2. A compound selected from:
including any tautomer thereof; or an isomer thereof in which the C26, 27 C═C bond shown as trans is cis; and including a methanol adduct thereof in which a ketal is formed by the combination of the C-53 keto and the C-15 hydroxyl group and methanol;
or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1 for use as a pharmaceutical.
4. A compound according to claim 1 for use as a pharmaceutical for the treatment of viral infections such as HCV or HIV infection or muscular dystrophy.
5. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable diluent or carrier.
6. The pharmaceutical composition according to claim 5 further comprising a second or subsequent active ingredient.
7. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable diluent or carrier.
8. The pharmaceutical composition according to claim 7 further comprising a second or subsequent active ingredient.